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Summary
The fate of microbial polysaccharides in host tissues is an important consideration because these
compounds are often immune modulators. Splenic marginal zone macrophages that express the C-
type lectin receptor SIGN-R1, take up neutral polysaccharides such as dextran and the capsular
polysaccharide of Streptococcus pneumoniae. Given that the major component of Cryptococcus
neoformans capsular polysaccharide, glucuronoxylomannan (GXM), localizes in the spleen when
injected intravenously, we investigated whether GXM uptake was mediated by splenic macrophages
expressing the SIGN-R1 receptor in mice. No significant differences in the amount and location of
GXM deposition were detected in the spleens of mice treated with a SIGN-R1 blocking antibody
when compared to controls. Similarly, a blocking antibody to Dectin-1, a co-receptor of -SIGN-R1,
had no effects on GXM distribution within the spleen. Histological examination of spleens from mice
and rats injected with FITC-Dextran and GXM revealed no significant co-localization, with Dextran
and GXM being found in marginal and red pulp macrophages, respectively. Hence we conclude that
GXM was not deposited in marginal zone macrophages. However, GXM deposition was found in
the red pulp. These results indicate that there is a selective localization of these polysaccharides to
different receptors such as SIGN-R1 for FITC dextran in marginal zone and a to-be-identified
receptor selectively expressed by red pulp macrophages for GXM.
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Introduction
The encapsulated yeast Cryptococcus neoformans, is a relatively frequent cause of
meningoencephalitis in immunocompromised individuals [1,2]. Patients with advanced HIV
infection are particularly vulnerable to cryptococcosis and antifungal therapy often fails to
eradicate the pathogen [3]. C. neoformans is unusual among eukaryotic microbes because it
contains a polysaccharide capsule with functional similarities to those of encapsulated bacteria
such as, Streptococcus pneumoniae and Haemophilus influenzae [4,5]. In fact, cryptococcal
polysaccharide is known to share some antigenic determinants with certain pneumococcal
polysaccharides [6,7]. The C. neoformans capsule is composed of glucuronoxylomannan
(GXM), galactoxylomannan (GalXM), and mannoprotein (MP), of which the major component
on a mass basis is GXM [8,9]. GXM can interfere with many aspects of immune function,
including leukocyte migration and phagocytosis [3,10–12]. The ability for GXM to interfere
with immune function is believed to contribute to C. neoformans virulence by allowing the
fungal cells to evade the immune system [11,13]. GXM is also attributed to causing
immunological paralysis, reducing the number of antibody producing cells in the spleen [10].
The spleen is intimately involved with the effective clearance of pathogens by the immune
system [14,15]. The major compartments of the spleen are the white and red pulp which are
separated by the marginal zone (MZ) The MZ contains highly phagocytic macrophages that
play a critical role in the spleen since it is the location where antigens that come into the
marginal sinuses from the bloodstream are initially screened [16,17]. Marginal zone
macrophages (MZM) also have been found to exclusively uptake neutral polysaccharides such
as Dextrans and Ficoll [16,18]. In contrast, acidic polysaccharides localize primarily to the red
pulp of the spleen [15,16,19]. The efficiency of this filtering system also results from the
vascular structure of the red pulp through which blood is slowed down, enabling macrophages
to phagocytose polysaccharide antigens [20].
The C-type lectin SIGN-related 1 (SIGN-R1) receptor is expressed on the macrophages of the
marginal zone of the spleen and on medullary and subcapsular macrophages in lymph nodes
[4,21,22]. SIGN-R1 is a mouse homologue of the DC-SIGN receptor found in dendritic cells.
DC-SIGN is functionally associated with several, critically important biological processes
including the ability to be hijacked by the HIV-1 virus, presentation and facilitating
transmission of the virus to CD4+ T-cells [14,21]. Recently it has been shown that SIGN-R1
can bind the complement C1 component C1q and assemble a C3 convertase against S.
pneumoniae infection [23]. Furthermore, the SIGN-R1 receptor in the marginal zone
macrophages can bind and internalize the capsular polysaccharide of Streptococcus
pneumoniae and Dextrans [4,22]. This phenomenon was demonstrated by using a transient
SIGN-R1 receptor knock out system (TKO), whereby the monoclonal antibody (mAb) 22D1
is used to selectively block receptor function [4,21,23].
Several studies of GXM sequestration and tissue localization revealed that although GXM is
rapidly cleared from the circulation with a half life of 1.1–2.7 days this is then followed by a
plateau with little elimination [24]. Intravenous administration of GXM in rats leads to the
deposition in tissue macrophages [24]. However little is known about the mechanism by which
GXM binds to macrophages or the fate of bound GXM [24]. In rats, GXM was found to localize
to the outer areas of the marginal zone by 5 hours after (i.v.) injection [1,3]. GXM deposition
in the spleen is accompanied by a rapid and intense burst of cytokine and chemokine expression
[3,24] Multiple receptors such as CD18, TLR4, CD14 and FCγRII may be involved in the
cellular uptake of GXM [25–27]. Since the SIGN-R1 receptor binds the Streptococcus
pneumoniae capsular polysaccharide we investigated whether it is also involved in binding to
C. neoformans GXM. Our results indicate that red pulp, but not marginal zone, macrophages
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are responsible for uptake of GXM by the spleen in a process whereby that SIGN-R1 is
dispensable.
Materials and Methods
Animals
C57BL/6, 6–8 week old, female mice were obtained from The Jackson Laboratories. Mice
were used for the intravenous (i.v.) injections with glucuronoxylomannan (GXM), FITC-
Dextran and PBS. Sprague Dawley (200–250 grams) rats were obtained from Harlan Sprague
Dawley, Inc. (Indianapolis, Indiana). Rats were used for the intravenous (i.v.) injections with
glucuronoxylomannan (GXM) and saline. Animals were sacrificed by asphyxiation with
CO2. All animal experiments were done according to institutional guidelines.
Antibodies
Monoclonal antibody (MAb) 22D1 was used for the transient knock out (TKO) of marginal
zone splenic macrophages possessing the SIGN-R1 receptor [21]. ChromePure Syrian Hamster
IgG from the Jackson Immunoresearch laboratories (Bar Harbor, Maine) was used as a control.
Polysaccharides
Fluorescein isothiocyanate- Dextran (FITC-Dextran) of MW 2,000 kDa was obtained from
Sigma-Aldrich (St Louis, MO). To study the uptake of the Dextran 100 µg (1mg/ml in sterile
PBS) of the polysaccharide was injected intravenous (i.v.) in mice. C. neoformans strain 24067
(serotype D) was obtained from the American Type Culture Collection (Rockville M.D.).
Cryptococcus neoformans polysaccharide (GXM) preparation was done as described
previously [28,29].
Administration of polysaccharide and mAb to mice
C57BL/6 mice were injected (i.v.) with 100 µg of either the MAb 22D1 or the control Syrian
Hamster IgG antibody in PBS, 24 hours prior to GXM or FITC-Dextran administration. An
amount of 100 ug of GXM or FITC-Dextran diluted in sterile PBS, was injected (i.v.) to each
mouse. Approximately 24 hours after polysaccharide infusion, the mice were sacrificed and
the spleens and livers were removed for analysis of polysaccharide content.
Immunofluorescence with FITC-Dextran
Organs from mice injected with FITC-Dextran were fixed with 10% buffered formalin and
embedded in paraffin. Tissues were sectioned into 4 um slices and placed on slides, that were
subsequently deparafinized and coated with 0.05M N-propyl gallate to preserve fluorescence.
Slides were maintained in the dark and at 4°C until ready for use. All slides were viewed using
an Olympus AX 70 microscope (Olympus America, Inc., Melville N.Y). Images were captured
with a QImaging Retiga 1300 digital camera using the QCapture Suite V2.46 software
(QImaging, Burnaby BC, Canada). Images were merged or contrast adjusted using Adobe
Photoshop 7.0 (San Jose, California).
Tissue Immunohistochemistry
Immunohistochemistry was used to localize GXM in splenic tissues using protocols that have
been described elsewhere [30]. Briefly, organs were fixed in 10% buffered formalin and
embedded in paraffin. Tissues were sectioned into 4 µm slices and placed on slides. Tissues
were then deparaffized using 100% xylene and an ethanol gradient of (90, 70, and 50 %). Slides
were first incubated in a 1:10 dilution of 30% H2O2 to extinguish all endogenous peroxidase
activity. Tissue was then blocked for an hour with a (1:20 dilution) of goat or horse serum
followed by incubation with a 1.94 µg /ml of MAb 18B7 for 1 hour at room temperature. Slides
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were washed 3 times with PBS for 15 minutes. As a secondary antibody, 4 µg /ml of goat anti
mouse IgG1- (HRP) conjugate (Southern Biotechnology, Birmingham, AL) was incubated for
1.5 hours. Unbound antibody was washed with PBS for 15 minutes. Diaminobenzidine (DAB
Chromogen) (Dako Corporation, Carpinteria, CA) was used as the substrate for the enzyme
conjugated to the secondary antibody to develop the reaction, brown color seen in tissue. The
tissues were then counterstained with hematoxylin, (Sigma Diagnostics, St.Louis, MO), to
facilitate contrast in splenic tissue. Two mice were not injected with GXM and were used as
controls (n = 3 mice/rats per group).
Temporal localization of GXM or FITC-Dextran in spleen
Mice were injected intravenously with 100 µg of GXM, FITC-Dextran or PBS. Spleens were
collected at 1, 3, 5, 12, and 24 hours after injected and processed for GXM concentration and
localization.
Organ Homogenization
Spleens and livers were homogenized and passed through a 0.20 µm Falcon cell strainer into
2 ml of sterile PBS. Homogenates were spun at 6,000 rpm for 10 min to remove cellular debris
and supernatants were digested with 20 µg /ml of Proteinase K prior to overnight incubation
at 37° C (Roche Diagnostics, Indianapolis, IN). Organ homogenates that were not used for
immediate analysis were stored at −20° C for up to 1 week.
Measurement of GXM in liver and spleen
GXM deposition in the liver and spleen was measured by capture ELISA as described (2).
Briefly, microtiter plates were coated with 1 µg /ml goat Ab to mouse IgG1 (Southern
Biotechnology, Birmingham, AL). MAb 18B7 to GXM was then added in a solution of 5 µg /
ml as the antigen capture antibody (Ab). Organ homogenate supernatant digested with
Proteinase-K was incubated at 100°C for 5 minutes to inactivate the enzyme, prior to incubation
in microtiter plate. The presence of GXM was then detected by the IgM MAb to GXM 12A1
followed by the addition of alkaline phosphatase conjugated mouse anti-IgM MAb. p-
Nitrophenyl Phosphate (PNPP) was used as the substrate for the alkaline phospatase.
Absorbance was measured at 405 nm and the amount of GXM in solution was calculated from
standard curves.
Conjugation of 18B7 and 2H1 with Alexa Fluor 546 and 488
Alexa Flour 546 and 488 protein labeling kit, Molecular Probes (Carlsbad, California) was
used to conjugate MAb 18B7 and 2H1 respectively following manufacturers instructions.
GXM Cellular deposition in spleen
C57BL/6, 6–8 week old, female mice were obtained from the Jackson Laboratories were
injected (i.v.) with 100 µg of FITC-Dextran immediately followed by (i.v.) injection with 100
µg of GXM. Twenty-four hours later the spleens were removed, sectioned and processed as
described above. Prior to GXM detection, deparifinized slides were treated as described
previously [31], and above. To detect GXM in tissue sections 3.9 µg/ml of MAb 18B7
conjugated with Alexa Fluor 546 was incubated at 37°C for 1.5 hours. Unbound antibody was
10 minutes with PBS. Sections were then coated with N-propyl gallate to preserve fluorescence.
To detect the F4/80 receptor, 2 µg /mlof MAb F4/80, Serotec (Raleigh, NC) was incubated for
1 hour at 37 ° C in a moist chamber. Sections were washed for 15 minutes with 1% BSA. For
studies using the MAb 18B7, mice were injected with either 100 µg of GXM or 100 µg of
FITC-Dextran immediately followed by 1.94 µg/ml of the MAb 18B7. Spleens were removed
at 5, 12, and 24 hours, each time point was done in duplicate.
De Jesus et al. Page 4
Med Mycol. Author manuscript; available in PMC 2010 February 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Dectin-1 and GXM
C57BL/6, 6–8 week old, female mice were obtained from the Jackson Laboratories were
injected i.v. with 65 µg of MAb 2A11 immediately followed by an equal amount of GXM or
FITC-Zymozan A from S .cerevisiae, Molecular Probes (Eugene, OR). The MAb 2A11 against
Dectin-1 was a kind gift of Dr. Gordon Brown, University of Cape Town, South Africa [32].
Twenty-four hours later the spleens were removed and sectioned. Prior to GXM detection,
deparrifinized slides were treated as described previously [31] and above. To detect GXM,
immunohistochemistry was performed as mentioned above.
Flow Cytometry
C57BL/6 female mice were injected (i.v.) with 100 µg of GXM in PBS or PBS, 24 hours prior
to sacrifice. Splenic macrophages were isolated by homogenization in DMEM supplemented
with 10% FCS, 10% NTC-109, 1% nonessential amino acids and1% Penicillin-Streptomycin.
Cells were spun at 1200 rpm for 5 minutes and red blood cells were lysed by resuspending
pellet in 0.17 M, ice cold NH4Cl buffer for 5 min. Pellet was resuspended in staining buffer
(1% FCS in PBS) and cell viability was determined by trypan blue staining. Cells were fixed
with 3.7 % formaldehyde for 5 minutes at room temperature. After fixation, cells were
permeabilized with 1% Triton X-100 for 3 minutes at room temperature. Cellular Fc receptors
were blocked with mouse Ab to Fc (FcyIII/II anti mouse CD16/CD32 for 30 min in 5% milk
with gentle rocking at room temperature. Approximately 5 × 107 cells were incubated for 30
minutes at room temperature with 2.0 ug/ml of MAbs F4/F80-APC (IgG2b) (Serotec, Raleigh,
NC), biotinylated ERTR9 (IgM) (BMA Biomedicals, Augst Switzerland) and indirectly
labeled with streptavidin anti-IgM-Texas red (Caltag Burlingame, CA). C. neoformans
monoclonal antibody 2H1 conjugated to Alexafluor-488 or a secondary anti-IgG1- FITC was
used to detect GXM. The F4/80 (IgG2b) MAb can recognize the F4/80 molecule in splenic red
pulp macrophages [31,33]. Marginal zone macrophages expressing SIGN-R1 are specifically
recognized by the MAb ERTR9 [21,34]. Cells were washed 3 times after antibody incubation
with staining buffer. Samples were stored at 4°C in the dark until FACS is performed using
Cell Quest. The percentage of gated cells represents a population of 10,000 events.
Statistical Analysis
Statistical analysis was done by the Kruskal Wallis test (Primer; McGraw Hill, New York,
NY).
Results
GXM Localization in the Spleen
To determine the location of the marginal zone macrophages and confirm the transient
inactivation of the SIGN-R1 receptor using 22D1, we administered FITC-labeled Dextran (i.v).
to mice and compared spleen localization in mice given mAb 22D1 or controls (Fig 1a–c) [4,
21]. In normal mice, FITC labeled Dextran localized to marginal zone macrophages, and these
cells appeared as rings around the white pulp (1a), when tissue sections are viewed with
fluorescent microscopy. In mice injected with the MAb 22D1, the rings of marginal zone
macrophages are no longer apparent by fluorescent microscopy because blocking the SIGN-
R1 receptor eliminated Dextran uptake (1c). In contrast, GXM did not localize to the marginal
zone twenty-four hours post GXM injection. GXM localized to the red pulp of the spleen in
the presence and absence of mAb 22D1 (Fig 1d–f).
Given that GXM was not observed in the marginal zone at twenty four hours we evaluated
earlier time intervals after (i.v.) infusion since it was possible that intra-splenic transport had
occurred by 24 hours [1]. Consequently, we evaluated the location of GXM deposition in the
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spleen at 1, 3, 5, 12, and 24 hours after (i.v.) injection. At all time intervals evaluated, GXM
was deposited in the red pulp and no deposition was apparent in the marginal zone (Fig 2). As
an additional control, we evaluated the tissue localization of FITC-Dextran in the spleen and
noted marginal zone deposition at all times evaluated, data not shown.
The amount of GXM deposited in the liver and the spleen was measured by capture ELISA.
The SIGN-R1 receptor was transiently blocked with the anti-SIGN-R1, MAb 22D1 and an IgG
was used as a control. (Fig 3) [35]. The results reveal that no statistical difference was apparent
between livers and spleens of mice injected with MAb 22D1 or the IgG control (p values for
22D1 and IgG were 0.480 and 0.724 for liver and spleen comparisons, respectively, by the
Kruskal Wallis statistic).
Dectin-1 is not involved in the binding of GXM
The β-glucan receptor Dectin-1 is a major macrophage receptor for the nonopsonic recognition
of yeast and yeast derivatives such as zymosan from Candida albicans [32,36]. SIGN-R1 is
also involved in the recognition of the yeast-derived particle zymosan. We evaluated the
possibility that the β-glucan receptor, Dectin-1 was involved in the binding of GXM since it
has been found to be cooperatively involved with SIGN-R1 [36]. Immunofluorescence and
immunohistochemistry on splenic sections showed that mAb 2A11 blocked the binding of
FITC-zymozan but not GXM (data not shown). GXM localized to the red pulp macrophages
in mice with and without blockage of Dectin-1.
GXM and Dextran do not Colocalize in macrophages in vivo
In the spleen, FITC-Dextran localized to the marginal zone while GXM was localized to the
red pulp. Merged images revealed that each polysaccharide localized to different areas of the
spleen (Fig 4 a–d). Additionally, we looked for GXM deposition in rats to investigate if species
specific differences were observed. In the rat spleen, FITC-Dextran localized to marginal zone
cells while GXM localized to the red pulp as in mice. However, we also noted that in rats GXM
and Dextran appeared to be at closer proximities than in mice (Fig 4 e–g). Additionally,
immunohistochemistry using the chromagen diaminobenzidine (DAB) revealed that GXM
deposition is in the red pulp of the rat spleen however GXM is in closer proximity to the white
pulp. This result is in contrast to mice where GXM deposits only in the red pulp (Figure 1d).
F4/80 and GXM Co-localize to the red pulp
Since red pulp macrophages express high levels of the F4/80 antigen we used this marker to
more conclusively establish the association between red pulp macrophages and GXM uptake
[19,37]. Immunofluorescence studies revealed that the signals from GXM as detected by 18B7-
Alexa Fluor 546 and FITC-F4/80 co-localized in spleen (Fig 5). Flow cytommetry was done
to quantify how many F4/80 cells bound GXM. The results reveal that only a modest 13% of
the cells were F4/80 and GXM double positive when background was subtracted (Figure not
shown).
Discussion
GXM is an immunomodulatory molecule that causes immunological paralysis in the spleen,
down regulates proinflammatory cytokines and inhibits leukocyte migration [10,38]. For many
years, studies have shown that shed GXM remains circulating in the blood after successful
antifungal treatment [3,27]. Since GXM has also been found to remain for long periods in the
host’s organs such as the brain, liver and spleen, studies have attempted to elucidate the possible
mechanisms by which macrophages use to sequester the polysaccharide antigen [24,39]. Our
results showed that GXM localized to the spleen, is sequestered by the red pulp in both mice
and rats. Since GXM did not localize to the marginal zone irrespective of the presence or
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absence of mAb to SIGN-R1 we conclude that marginal zone macrophages are not involved
in GXM sequestration or processing. In fact, GXM localization was consistently associated
with red pulp macrophages. Further validation that GXM does not localize to marginal zone
macrophages comes from our ELISA studies where mice immunized with 22D1 and an IgG
control antibody reveal identical GXM concentration per organ mass.
These results are consistent with the observation that marginal zone macrophages (MZM) bind
to neutral polysaccharides such as dextrans and pneumococcal polysaccharides, whereas red
pulp acid residues that branch from the mannosyl backbone of GXM [40]. Our in vivo data
suggest that there may be distinct receptors that recognize neutral (Dextrans) and acidic (GXM)
polysaccharides.
Our results indicate that either SIGN-R1 is not the cellular receptor for GXM in mice or that
there is redundancy in the types of cellular receptors that can interact with this polysaccharide
such that cellular uptake does not require SIGN-R1. GXM is known to bind to other receptors
such as CD18 and CD14 in neutrophils [41]. Other studies have also suggested that GXM can
bind in vitro with TLR2 and TLR 4 [26,27]. It has also been shown that GXM can also induce
the activation of Fas Ligand in macrophages that in turn induces the apoptosis in T-cells [12].
Currently, there are no studies that suggest that marginal zone macrophages express receptors
that are associated with GXM uptake and this study validates that SIGN-R1 is dispensable.
We noted kinetic differences in the macrophage uptake of GXM and FITC-Dextran. GXM
localized to the red pulp within 1 h of (i.v.) administration. In contrast, at 1 hour FITC-Dextran
was only beginning to localize to the marginal zone. At later times, GXM localized to the red
pulp and FITC-Dextran localizes to the marginal zone macrophages. This observation is
modestly different than what is seen in rats. It has been reported that in rats GXM is localized
primarily to macrophages of the outer marginal zone within 5 hours [1]. We investigated if
there were any species specific differences in the localization of Dextran and GXM between
mice and rats. In both species, Dextrans localized to the marginal zone and GXM to the red
pulp. However, in rats GXM is in closer proximity to the MZ. We also investigated if the beta-
glucan receptor Dectin-1 was a possible receptor for GXM since studies suggested that SIGN-
R1 cooperates with Dectin-1 in the non-opsonic recognition of zymosan [36]. The results
indicate that like SIGN-R1, Dectin-1 is not involved in GXM uptake.
Since the spleen contains a variety of different cell populations that can independently bind
GXM and FITC-Dextran we used flow cytommetry to identify cell types that could potentially
interact with GXM. The results using the F4/80 a red pulp macrophage marker showed that
only a modest 12% of F4/80 macrophages are double positive with GXM. This result implies
that GXM may be bound by more than one receptor in the red pulp.
In summary, we report that red pulp but not marginal zone macrophages are responsible for
the uptake of the capsular polysaccharide component GXM of C. neoformans in a process
whereby the SIGN-R1 is dispensable. In light of this evidence, uncovering the location of were
GXM localizes in the spleen can allow for the further dissection at a molecular level of other
receptor types that are affected in C. neoformans pathogenesis.
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Figure 1. Immunofluorescence and immunohistochemistry of spleen tissue from mice injected with
FITC-dextran or GXM in the presence and absence of mAb to SIGN-R1
Panels show immunofluorescence for splenic sections from mice injected with FITC-dextran
alone (A), FITC-dextran and control mAb (B) and FITC-dextran and mAb 22D1 to SIGN-R1
(C). GXM in mouse spleen visualized by immunohistochemistry shows deposition (brown
color) outside the marginal zone with (D) or without (E) SIGN-R1 blockage. Panel F shows
GXM localization in the red pulp after injection with control IgG. Scale = 296 microns inner
diameter of marginal zone.
De Jesus et al. Page 11
Med Mycol. Author manuscript; available in PMC 2010 February 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Localization of GXM at different times
Immunohistochemistry on paraffin sections containing GXM localization (brown color) after
sacrificing the mice at 1hr (A) 3hrs (B) 5 hrs (C) 12 hrs (D) and 24 hrs (E). As a control mice
injected with PBS (Phosphate Buffered Saline) is also shown (F). Scale = 108 microns from
the outermost part of the marginal zone into the red pulp.
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Figure 3. Organ GXM content as measured by capture ELISA
Figure 4A shows GXM deposition in liver (solid bars) and spleen (striated bars) in the presence
of MAb 22D1. 4B shows GXM deposition in liver (solid bars) and spleen (striated bars) in the
presence of the Armenian hamster MAb IgG (control). n = 4 per group. Control group received
saline. Comparison of GXM concentration in liver (3.74 ± 0.61 ug/ml/g) and spleen (9.64 ±
4.2 ug/ml/g) homogenates from mice given mAb 22D1 revealed a significantly greater amount
of GXM in the spleen when normalized by organ mass. GXM concentrations in mice that
received the IgG control antibody were (4.81 ± 2.98 ug/ml/g in liver and (11.9 ± 7.84 ug/ml/
g) in spleen. In mice receiving GXM alone, the results in the liver and spleen were (3.9±1.45
ug/ml/g) and (13.0 ± 4.8 ug/ml/g).
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Figure 4. Dextran and GXM binding in splenic macrophages in mice and rats
Immunofluorescence of GXM and FITC-Dextran was observed in the spleen as follows: In
C57BL/6 mice FITC-Dextran (A) and GXM detected with MAb 18B7 conjugated with Alexa
Fluor 546 (B) in splenic tissue. Panel C shows merging of images from Panels A and B. Panel
D is shown as a background control since splenic tissue can autofluoresce if not blocked. In
Sprague Dawley rats FITC-Dextran (Panel E) and GXM detected with MAb 18B7 conjugated
with Alexa Fluor 546 (Panel F) in splenic tissue. Panel G shows merging of images from Panels
A and B. Scale bar = 69 microns.
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Figure 5. Immunofluorescence of spleen tissue after staining with the F4/80 macrophage marker
and GXM
Panel A, the F4/80 cell surface marker is detected by anti-F4/80-FITC MAb (green). Panel B,
GXM is detected by 18B7-Alexa Fluor 546 (red). Panel C, is the merged image. Scale = 110
microns.
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